de Ionne Jones

De Ionne Jones serves as a key procurement lead within the Administration for Strategic Preparedness and Response (ASPR), supporting the agency’s mission to ensure national readiness for public health emergencies through strategic acquisition of medical countermeasures and biomedical infrastructure. Responsible for managing complex contracting actions aligned with federal emergency response priorities, Jones oversees the procurement of research, development, and production capabilities critical to pandemic preparedness and biological threat mitigation. Their work directly enables the rapid deployment of diagnostics, therapeutics, and supply chain assets essential to national health security, with a focus on accelerating acquisition timelines under public health emergency authorities. Jones engages with a diverse range of vendors specializing in biotechnology research and animal production systems, fostering partnerships with firms capable of scaling high-containment manufacturing and novel therapeutic development. While no specific contractor relationships are currently identifiable in the data, their procurement patterns suggest collaboration with entities possessing advanced biosafety capabilities, GMP-certified production facilities, and experience in federal biomedical contracting under BARDA and HHS prime agreements. Relationships are typically performance-driven, emphasizing technical agility, regulatory compliance, and supply chain resilience. Jones demonstrates a strong preference for open competition, with 100% of acquisitions conducted without set-asides, indicating a focus on capability over socioeconomic classification. This approach prioritizes mission-critical outcomes and rapid scalability over traditional small business set-aside programs, though small businesses may still participate as subcontractors or through general solicitations. The primary procurement focus centers on NAICS 541714 (Biotechnology R&D) and 112990 (All Other Animal Production), reflecting expertise in developing next-generation vaccines, monoclonal antibodies, and animal-derived biological materials for countermeasure production. Jones specializes in acquiring advanced biomanufacturing services, preclinical research models, and high-containment biosafety infrastructure essential to sustaining the nation’s biomedical industrial base.